As a result, the majority of genomic alterations are distinct between squamous (e.g., cyclin dependent kinase inhibitor 2A (CDKN2A) and tumor protein p53 (TP53)) and adenocarcinoma (e.g., KRAS proto‐oncogene (KRAS) and epidermal growth factor receptor (EGFR)) NSCLC.7 This evidence concerns the gene TP53 and non-small cell lung carcinoma.